請用此 Handle URI 來引用此文件:
http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/66664
完整後設資料紀錄
DC 欄位 | 值 | 語言 |
---|---|---|
dc.contributor.advisor | 李財坤(Tsai-Kun Li) | |
dc.contributor.author | Yng-Miin Toh | en |
dc.contributor.author | 卓盈敏 | zh_TW |
dc.date.accessioned | 2021-06-17T00:49:48Z | - |
dc.date.available | 2021-11-29 | |
dc.date.copyright | 2012-03-02 | |
dc.date.issued | 2011 | |
dc.date.submitted | 2011-11-30 | |
dc.identifier.citation | 1. Berenblum, I., Carcinogenesis as a biological problem. Frontiers of biology. 1974, Amsterdam New York: North-Holland Pub. Co. ;American Elsevier Pub. Co. xxvii, 376 p.
2. Boveri, T., Zur Frage der Entstehung maligner Tumoren. Gustav Fischer Verlag, Jena, Germany., 1914. 3. Boveri, T., Concerning the origin of malignant tumours by Theodor Boveri. Translated and annotated by Henry Harris. J Cell Sci, 2008. 121 Suppl 1: p. 1-84. 4. Stratton, M.R., Exploring the genomes of cancer cells: progress and promise. Science, 2011. 331(6024): p. 1553-8. 5. Hahn, W.C. and R.A. Weinberg, Rules for making human tumor cells. N Engl J Med, 2002. 347(20): p. 1593-603. 6. Hanahan, D. and R.A. Weinberg, The hallmarks of cancer. Cell, 2000. 100(1): p. 57-70. 7. Bissell, M.J. and W.C. Hines, Why don't we get more cancer? A proposed role of the microenvironment in restraining cancer progression. Nat Med, 2011. 17(3): p. 320-9. 8. Hanahan, D. and R.A. Weinberg, Hallmarks of cancer: the next generation. Cell, 2011. 144(5): p. 646-74. 9. van Kempen, L.C., et al., The tumor microenvironment: a critical determinant of neoplastic evolution. Eur J Cell Biol, 2003. 82(11): p. 539-48. 10. Vaupel, P., Tumor microenvironmental physiology and its implications for radiation oncology. Semin Radiat Oncol, 2004. 14(3): p. 198-206. 11. Tannock, I.F., Tumor physiology and drug resistance. Cancer Metastasis Rev, 2001. 20(1-2): p. 123-32. 12. Gardner, L.B. and P.G. Corn, Hypoxic regulation of mRNA expression. Cell Cycle, 2008. 7(13): p. 1916-24. 13. Vaupel, P. and A. Mayer, Hypoxia in cancer: significance and impact on clinical outcome. Cancer Metastasis Rev, 2007. 26(2): p. 225-39. 14. Semenza, G.L., Hypoxia and cancer. Cancer Metastasis Rev, 2007. 26(2): p. 223-4. 15. Li, Y. and D. Ye, Cancer Therapy By Targeting Hypoxia-Inducible Factor-1. Curr Cancer Drug Targets, 2010. 10: p. 782-96. 16. Brahimi-Horn, M.C., J. Chiche, and J. Pouyssegur, Hypoxia and cancer. J Mol Med, 2007. 85(12): p. 1301-7. 17. Chi, J.T., et al., Gene expression programs in response to hypoxia: cell type specificity and prognostic significance in human cancers. PLoS Med, 2006. 3(3): p. e47. 18. Semenza, G.L., Targeting HIF-1 for cancer therapy. Nat Rev Cancer, 2003. 3(10): p. 721-32. 19. Harris, A.L., Hypoxia--a key regulatory factor in tumour growth. Nat Rev Cancer, 2002. 2(1): p. 38-47. 20. Hockel, M. and P. Vaupel, Tumor hypoxia: definitions and current clinical, biologic, and molecular aspects. J Natl Cancer Inst, 2001. 93(4): p. 266-76. 21. Semenza, G.L., Intratumoral hypoxia, radiation resistance, and HIF-1. Cancer Cell, 2004. 5(5): p. 405-6. 22. Semenza, G.L., Evaluation of HIF-1 inhibitors as anticancer agents. Drug Discov Today, 2007. 12(19-20): p. 853-9. 23. Rankin, E.B. and A.J. Giaccia, The role of hypoxia-inducible factors in tumorigenesis. Cell Death Differ, 2008. 15(4): p. 678-85. 24. Wang, G.L. and G.L. Semenza, Purification and characterization of hypoxia-inducible factor 1. J Biol Chem, 1995. 270(3): p. 1230-7. 25. Wang, G.L., et al., Hypoxia-inducible factor 1 is a basic-helix-loop-helix-PAS heterodimer regulated by cellular O2 tension. Proc Natl Acad Sci U S A, 1995. 92(12): p. 5510-4. 26. Wiesener, M.S., et al., Widespread hypoxia-inducible expression of HIF-2alpha in distinct cell populations of different organs. FASEB J, 2003. 17(2): p. 271-3. 27. Gu, Y.Z., et al., Molecular characterization and chromosomal localization of a third alpha-class hypoxia inducible factor subunit, HIF3alpha. Gene Expr, 1998. 7(3): p. 205-13. 28. Hara, S., et al., Expression and characterization of hypoxia-inducible factor (HIF)-3alpha in human kidney: suppression of HIF-mediated gene expression by HIF-3alpha. Biochem Biophys Res Commun, 2001. 287(4): p. 808-13. 29. Pasanen, A., et al., Hypoxia-inducible factor (HIF)-3alpha is subject to extensive alternative splicing in human tissues and cancer cells and is regulated by HIF-1 but not HIF-2. Int J Biochem Cell Biol. 42(7): p. 1189-200. 30. Heikkila, M., et al., Roles of the human hypoxia-inducible factor (HIF)-3alpha variants in the hypoxia response. Cell Mol Life Sci. 68(23): p. 3885-901. 31. Lisy, K. and D.J. Peet, Turn me on: regulating HIF transcriptional activity. Cell Death Differ, 2008. 15(4): p. 642-9. 32. Schofield, C.J. and P.J. Ratcliffe, Oxygen sensing by HIF hydroxylases. Nat Rev Mol Cell Biol, 2004. 5(5): p. 343-54. 33. Giaccia, A., B.G. Siim, and R.S. Johnson, HIF-1 as a target for drug development. Nat Rev Drug Discov, 2003. 2(10): p. 803-11. 34. Maher, E.R., H.P. Neumann, and S. Richard, von Hippel-Lindau disease: a clinical and scientific review. Eur J Hum Genet, 2011. 19(6): p. 617-23. 35. Maxwell, P.H., et al., The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis. Nature, 1999. 399(6733): p. 271-5. 36. Ohh, M., et al., Ubiquitination of hypoxia-inducible factor requires direct binding to the beta-domain of the von Hippel-Lindau protein. Nat Cell Biol, 2000. 2(7): p. 423-7. 37. Melillo, G., Targeting hypoxia cell signaling for cancer therapy. Cancer Metastasis Rev, 2007. 26(2): p. 341-52. 38. Bardos, J.I. and M. Ashcroft, Negative and positive regulation of HIF-1: a complex network. Biochim Biophys Acta, 2005. 1755(2): p. 107-20. 39. Majumder, P.K., et al., mTOR inhibition reverses Akt-dependent prostate intraepithelial neoplasia through regulation of apoptotic and HIF-1-dependent pathways. Nat Med, 2004. 10(6): p. 594-601. 40. Hudson, C.C., et al., Regulation of hypoxia-inducible factor 1alpha expression and function by the mammalian target of rapamycin. Mol Cell Biol, 2002. 22(20): p. 7004-14. 41. Sapra, P., et al., Novel delivery of SN38 markedly inhibits tumor growth in xenografts, including a camptothecin-11-refractory model. Clin Cancer Res, 2008. 14(6): p. 1888-96. 42. Lee, K., et al., Anthracycline chemotherapy inhibits HIF-1 transcriptional activity and tumor-induced mobilization of circulating angiogenic cells. Proc Natl Acad Sci U S A, 2009. 106(7): p. 2353-8. 43. Creighton-Gutteridge, M., et al., Cell type-specific, topoisomerase II-dependent inhibition of hypoxia-inducible factor-1alpha protein accumulation by NSC 644221. Clin Cancer Res, 2007. 13(3): p. 1010-8. 44. Zhang, H., et al., Digoxin and other cardiac glycosides inhibit HIF-1alpha synthesis and block tumor growth. Proc Natl Acad Sci U S A, 2008. 105(50): p. 19579-86. 45. Alberts, D.S., et al., Pharmacology of mitoxantrone: mode of action and pharmacokinetics. Invest New Drugs, 1985. 3(2): p. 101-7. 46. Derwenskus, J., Current disease-modifying treatment of multiple sclerosis. Mt Sinai J Med, 2011. 78(2): p. 161-75. 47. White, R.J. and F.E. Durr, Development of mitoxantrone. Invest New Drugs, 1985. 3(2): p. 85-93. 48. Nitiss, J.L., Targeting DNA topoisomerase II in cancer chemotherapy. Nat Rev Cancer, 2009. 9(5): p. 338-50. 49. Neuhaus, O., B.C. Kieseier, and H.P. Hartung, Mechanisms of mitoxantrone in multiple sclerosis--what is known? J Neurol Sci, 2004. 223(1): p. 25-7. 50. Rapisarda, A., et al., Topoisomerase I-mediated inhibition of hypoxia-inducible factor 1: mechanism and therapeutic implications. Cancer Res, 2004. 64(4): p. 1475-82. 51. Hsin, L.W., et al., Synthesis, DNA binding, and cytotoxicity of 1,4-bis(2-amino-ethylamino)anthraquinone-amino acid conjugates. Bioorg Med Chem, 2008. 16(2): p. 1006-14. 52. Hsiao, C.J., et al., WRC-213, an l-methionine-conjugated mitoxantrone derivative, displays anticancer activity with reduced cardiotoxicity and drug resistance: identification of topoisomerase II inhibition and apoptotic machinery in prostate cancers. Biochem Pharmacol, 2008. 75(4): p. 847-56. 53. Y.C. Bor, J.S., Y. Li, J. Coyle, D. Rekosh and Marie-Louise Hammarskjold, Northern Blot analysis of mRNA from mammalian polyribosomes. Nature protocols, 2006. 54. Fong, G.H. and K. Takeda, Role and regulation of prolyl hydroxylase domain proteins. Cell Death Differ, 2008. 15(4): p. 635-41. 55. Wang, G.L. and G.L. Semenza, Desferrioxamine induces erythropoietin gene expression and hypoxia-inducible factor 1 DNA-binding activity: implications for models of hypoxia signal transduction. Blood, 1993. 82(12): p. 3610-5. 56. Alberts, D.S., et al., Disposition of mitoxantrone in cancer patients. Cancer Res, 1985. 45(4): p. 1879-84. 57. Ehninger, G., et al., Clinical pharmacology of mitoxantrone. Cancer Treat Rep, 1986. 70(12): p. 1373-8. 58. Marxsen, J.H., et al., Hypoxia-inducible factor-1 (HIF-1) promotes its degradation by induction of HIF-alpha-prolyl-4-hydroxylases. Biochem J, 2004. 381(Pt 3): p. 761-7. 59. Wiesener, M.S., et al., Induction of endothelial PAS domain protein-1 by hypoxia: characterization and comparison with hypoxia-inducible factor-1alpha. Blood, 1998. 92(7): p. 2260-8. 60. Fan, J.R., et al., Cellular processing pathways contribute to the activation of etoposide-induced DNA damage responses. DNA Repair (Amst), 2008. 7(3): p. 452-63. 61. Li, T.K. and L.F. Liu, Tumor cell death induced by topoisomerase-targeting drugs. Annu Rev Pharmacol Toxicol, 2001. 41: p. 53-77. 62. Harker, W.G., et al., Mitoxantrone resistance in HL-60 leukemia cells: reduced nuclear topoisomerase II catalytic activity and drug-induced DNA cleavage in association with reduced expression of the topoisomerase II beta isoform. Biochemistry, 1991. 30(41): p. 9953-61. 63. Harker, W.G., et al., Selective use of an alternative stop codon and polyadenylation signal within intron sequences leads to a truncated topoisomerase II alpha messenger RNA and protein in human HL-60 leukemia cells selected for resistance to mitoxantrone. Cancer Res, 1995. 55(21): p. 4962-71. 64. Carpenter, A.J. and A.C. Porter, Construction, characterization, and complementation of a conditional-lethal DNA topoisomerase IIalpha mutant human cell line. Mol Biol Cell, 2004. 15(12): p. 5700-11. 65. Drake, F.H., et al., Biochemical and pharmacological properties of p170 and p180 forms of topoisomerase II. Biochemistry, 1989. 28(20): p. 8154-60. 66. Huang, L.E., et al., Regulation of hypoxia-inducible factor 1alpha is mediated by an O2-dependent degradation domain via the ubiquitin-proteasome pathway. Proc Natl Acad Sci U S A, 1998. 95(14): p. 7987-92. 67. Ravi, R., et al., Regulation of tumor angiogenesis by p53-induced degradation of hypoxia-inducible factor 1alpha. Genes Dev, 2000. 14(1): p. 34-44. 68. Yang, J., et al., Small-molecule activation of p53 blocks hypoxia-inducible factor 1alpha and vascular endothelial growth factor expression in vivo and leads to tumor cell apoptosis in normoxia and hypoxia. Mol Cell Biol, 2009. 29(8): p. 2243-53. 69. Kaluzova, M., et al., DNA damage is a prerequisite for p53-mediated proteasomal degradation of HIF-1alpha in hypoxic cells and downregulation of the hypoxia marker carbonic anhydrase IX. Mol Cell Biol, 2004. 24(13): p. 5757-66. 70. Choi, Y.J., et al., HIF-1alpha modulation by topoisomerase inhibitors in non-small cell lung cancer cell lines. J Cancer Res Clin Oncol, 2009. 135(8): p. 1047-53. 71. Fortune, J.M. and N. Osheroff, Topoisomerase II as a target for anticancer drugs: when enzymes stop being nice. Prog Nucleic Acid Res Mol Biol, 2000. 64: p. 221-53. 72. Burger, K., et al., Chemotherapeutic drugs inhibit ribosome biogenesis at various levels. J Biol Chem, 2010. 285(16): p. 12416-25. 73. Durr, F.E., R.E. Wallace, and R.V. Citarella, Molecular and biochemical pharmacology of mitoxantrone. Cancer Treat Rev, 1983. 10 Suppl B: p. 3-11. 74. Zheng, S., et al., Structural basis for stabilization of the tau pre-mRNA splicing regulatory element by novantrone (mitoxantrone). Chem Biol, 2009. 16(5): p. 557-66. 75. Moeller, B.J., et al., Radiation activates HIF-1 to regulate vascular radiosensitivity in tumors: role of reoxygenation, free radicals, and stress granules. Cancer Cell, 2004. 5(5): p. 429-41. 76. Moeller, B.J., et al., Pleiotropic effects of HIF-1 blockade on tumor radiosensitivity. Cancer Cell, 2005. 8(2): p. 99-110. 77. Williams, K.J., et al., Enhanced response to radiotherapy in tumours deficient in the function of hypoxia-inducible factor-1. Radiother Oncol, 2005. 75(1): p. 89-98. 78. Comerford, K.M., et al., Hypoxia-inducible factor-1-dependent regulation of the multidrug resistance (MDR1) gene. Cancer Res, 2002. 62(12): p. 3387-94. 79. Hussein, D., et al., Chronic hypoxia promotes hypoxia-inducible factor-1alpha-dependent resistance to etoposide and vincristine in neuroblastoma cells. Mol Cancer Ther, 2006. 5(9): p. 2241-50. 80. Schwartz, D.L., et al., The selective hypoxia inducible factor-1 inhibitor PX-478 provides in vivo radiosensitization through tumor stromal effects. Mol Cancer Ther, 2009. 8(4): p. 947-58. 81. Faulds, D., et al., Mitoxantrone. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in the chemotherapy of cancer. Drugs, 1991. 41(3): p. 400-49. | |
dc.identifier.uri | http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/66664 | - |
dc.description.abstract | 實質固態瘤(solid tumor)大都處在一個缺氧的微環境中,而參與缺氧調節的核心因子-缺氧誘導因子-1α(hypoxia-inducible factor-1α,HIF-1α)在腫瘤的發生及進程以及腫瘤細胞對化療及放射線治療的耐受性上扮演著極為重要的角色。因此,HIF-1α是很有潛力的腫瘤治療標的物。在本論文中,我們發現一個新型HIF-1α抑制劑並深入探討該藥物抑制HIF-1α的分子機制。我們分析了臨床藥物拓撲異構酶Ⅱ(topoisomerase II,TOP2)抑制劑對於HIF-1α表現的抑制效果,並以mitoxantrone(MX)為重點藥物做進一步的研究。出乎意料的是,利用藥理性抑制、RNA干擾技術以及TOP2突變型細胞株,我們發現MX抑制HIF-1α的機制並不透過TOP2。MX也不影響HIF-1α的蛋白穩定度及RNA轉錄(transcription)程度,但其抑制卻與cycloheximide的作用機制類似。這些實驗間接說明了MX抑制了HIF-1α的轉譯(translation)。利用體外轉譯(in vitro translation)HIF-1α mRNA的方法也進一步證實MX能夠抑制HIF-1α的轉譯。有趣的是,細胞在處理MX後,多核醣體(polysome)上的VEGF-A mRNA如預期的減少但是HIF-1α mRNA卻有些許地增加。因此,我們猜測MX有可能抑制了HIF-1α mRNA在轉譯延長(translation elongation)的步驟。綜合上述的實驗結果,我們認為MX除了能夠抑制TOP2還另外具有抑制HIF-1α的能力,開廣了MX在癌症治療上的應用範圍及效力。 | zh_TW |
dc.description.abstract | Solid tumors encounter a growth-limiting hypoxic microenvironment as they develop. Hypoxia-inducible factors (HIF) play important roles in hypoxia-associated tumor development and therapeutic resistance. Targeting the HIF pathway (especially HIF-1α) represents a promising cancer treatment strategy. In this dissertation, a novel class of HIF-1α inhibitors and the possible molecular basis of inhibition were studied. We analyzed the inhibitory effects of clinically used topoisomerase II (TOP2)-targeting drugs on HIF-1α expression with a primary focus on mitoxantrone (MX), which showed the most potent inhibitory effect. The potential role of TOP2 in MX-inhibited HIF-1α expression was studied using pharmacological inhibition, a knockdown approach and TOP2 mutant cells. Moreover, involvement of MX in proteasome-mediated degradation, transcription and translation of HIF-1α was examined. The TOP2-targeting MX, but neither doxorubicin nor etoposide, strongly inhibited HIF-1α expression under hypoxic conditions in a dose- and time-dependent manner. Surprisingly, the MX-mediated inhibition of HIF-1α expression was largely independent of two TOP2 isozymes, proteasomal degradation and transcription. Furthermore, MX inhibited HIF-1α expression and function in a similar fashion as cycloheximide, suggesting that MX might inhibit HIF-1α via a blockage at its translation step. In vitro translation experiments using HIF-1α mRNA further confirmed inhibition of HIF-1α translation by MX. Interestingly, levels of the polysome-bound HIF-1α and VEGF-A mRNA were elevated and decreased after MX treatment, respectively. In conclusions, we have identified the TOP2-targeting compound, MX, as a HIF-1α inhibitor possibly through a translation inhibition mechanism, suggesting the possibility of an additional anticancer activity for MX. | en |
dc.description.provenance | Made available in DSpace on 2021-06-17T00:49:48Z (GMT). No. of bitstreams: 1 ntu-100-F95445107-1.pdf: 3887164 bytes, checksum: d888bdd50a80dbdc41cafd1f6e107859 (MD5) Previous issue date: 2011 | en |
dc.description.tableofcontents | 口試委員會審定書 i
中文摘要 ii Abstract iii Chapter I 1 The Tumor Microenvironment and Anticancer Drug Development: An Overview 1 1.1 Tumor microenvironment 2 1.1.1 The relationship between hypoxia and tumorigenesis 3 1.1.2 Overview of the HIF pathway 4 1.1.2.1 Structure and function of HIFs 5 1.1.2.2 Regulation of HIF 6 1.1.3 Inhibiton of HIF-1α as a potential anticancer strategy 7 1.2 Topoisomerase II-targeting compound-Mitoxantrone 8 1.3 Specific aims: an idea about old weapon with new target 8 Chapter II 10 Materials and Methods 10 2.1 Cell lines and reagents 11 2.2 Cell culture (normoxia vs. hypoxia) 11 2.3 Immunoblot analysis and antibodies 12 2.4 RNA isolation 12 2.5 cDNA synthesis and reverse transcription-polymerase chain reaction (RT-PCR) 14 2.6 Lentivirus-mediated RNA interference technology 15 2.7 In vitro transcription and translation 16 2.8 Isolation of polysome-associated mRNA 16 2.9 Transient transfection 17 2.10 Flow cytometry analysis 17 2.11 Quantitative measurements and statistic analyses 18 Chapter III 19 Results 19 3.1 MX inhibits HIF-1α protein accumulation 20 3.2 MX inhibits HIF-1α protein accumulation in a concentration- and time-dependent manner 21 3.3 MX and its amino acid-conjugated derivatives differentially inhibits HIF-1α protein accumulation 21 3.4 Inhibition of HIF-1α expression by MX is largely independent of both TOP2 isozymes 22 3.5 MX does not affect degradation of HIF-1α protein 23 3.6 MX induces expression of HIF-1α mRNA 24 3.7 MX inhibits HIF-1α expression at the translation step 25 3.8 MX inhibits HIF-1α expression in a PI3K/Akt/mTOR-independent pathway 26 3.9 MX inhibits HIF-1α expression in a p53-independent pathway 26 3.10 MX affects polysome formation and translation of HIF-1α mRNA 27 Chapter IV 28 Discussion 28 Chapter V 33 Figures 33 References 68 Appendix: Curriculum Vitae 76 | |
dc.language.iso | en | |
dc.title | 探討mitoxantrone抑制缺氧誘導因子-1α的機制 | zh_TW |
dc.title | Study on the inhibitory mechanism of mitoxantrone on HIF-1α pathway | en |
dc.type | Thesis | |
dc.date.schoolyear | 100-1 | |
dc.description.degree | 博士 | |
dc.contributor.oralexamcommittee | 顧記華(Jih-Hwa Guh),鄧述諄(Shu-Chun Teng),賴逸儒(I-Rue Lai),沈湯龍(Tang-Long Shen) | |
dc.subject.keyword | 缺氧誘導因子-1α,mitoxantrone,缺氧,轉譯,拓撲異構酶, | zh_TW |
dc.subject.keyword | HIF-1α,mitoxantrone,hypoxia,translation,topoisomerase, | en |
dc.relation.page | 79 | |
dc.rights.note | 有償授權 | |
dc.date.accepted | 2011-11-30 | |
dc.contributor.author-college | 醫學院 | zh_TW |
dc.contributor.author-dept | 微生物學研究所 | zh_TW |
顯示於系所單位: | 微生物學科所 |
文件中的檔案:
檔案 | 大小 | 格式 | |
---|---|---|---|
ntu-100-1.pdf 目前未授權公開取用 | 3.8 MB | Adobe PDF |
系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。